Categories: HospitalsNews

Encision Reports Second Quarter Fiscal Year 2024 Results

BOULDER, CO / ACCESSWIRE / November 14, 2023 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 second quarter that ended September 30, 2023.

The Company posted quarterly product net revenue of $1.75 million and service net revenue of $74 thousand, or total net revenue of $1.83 million for a quarterly net loss of $7 thousand, or $0.00 per diluted share. These results compare to product net revenue of $1.70 million and no service net revenue, or total net revenue of $1.70 million for a quarterly net loss of $279 thousand, or $(0.02) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 47% in the fiscal 2024 second quarter and 49% in the fiscal 2023 second quarter.

The Company posted six months product net revenue of $3.37 million and service net revenue of $114 thousand, or total net revenue of $3.48 million for a six-month net loss of $148 thousand, or $(0.01) per diluted share. These results compare to product net revenue of $3.40 million and service net revenue of $459 thousand, or total net revenue of $3.86 million for a six-month net loss of $15 thousand, or $0.00 per diluted share, in the year-ago six months. Gross margin on product net revenue was 50% in the fiscal 2024 six months and 49% in the fiscal 2023 six months.

“The fiscal 2024 second quarter presented significant challenges for Encision and for the medical device market in general,” said Gregory Trudel, President and CEO of Encision Inc. “The demand for surgical procedures was diminished during the pandemic period and its rebound has been a slow process. The market has seen a number of positive indicators for an increase in demand and Encision continues to drive toward them. The service revenue that we were able to drive in the previous year was very helpful and we are working to recreate that revenue stream with new partners and opportunities to collaborate on our foundational technologies.”

Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company’s actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company’s distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company’s filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)

Three Months Ended Six Months Ended
September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022
Product revenue
$ 1,752 $ 1,704 $ 3,366 $ 3,400
Service revenue
74 114 459
Total revenue
1,826 1,704 3,480 3,859
Product cost of revenue
927 872 1,697 1,743
Service cost of revenue
37 58
Total cost of revenue
964 872 1,755 1,743
Gross profit
862 832 1,725 2,116
Operating expenses:
Sales and marketing
389 490 823 993
General and administrative
366 397 755 742
Research and development
101 223 269 393
Total operating expenses
856 1,110 1,847 2,128
Operating income (loss)
6 (278 ) (122 ) (12 )
Interest expense and other income, net
(13 ) (1 ) (26 ) (3 )
(Loss) before provision for income taxes
(7 ) (279 ) (148 ) (15 )
Provision for income taxes
Net (loss)
$ (7 ) $ (279 ) $ (148 ) $ (15 )
Net (loss) per share-basic and diluted
$ 0.00 $ (0.02 ) $ (0.01 ) $ 0.00
Weighted average shares-basic and diluted
11,770 11,752 11,770 11,735

Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)

September 30, 2023 March 31, 2023
ASSETS
Cash
$ 306 $ 189
Accounts receivable
1,025 921
Inventories, net
1,642 1,899
Prepaid expenses
53 116
Total current assets
3,026 3,125
Equipment, net
272 303
Right of use asset
1,169 496
Patents, net
167 163
Other assets
55 47
Total assets
$ 4,689 $ 4,134
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable
$ 300 $ 253
Secured notes
44 44
Line of credit
339 177
Accrued compensation
167 218
Other accrued liabilities
41 85
Accrued lease liability
273 354
Total current liabilities
1,164 1,131
Secured notes
256 268
Accrued lease liability
896 240
Total liabilities
2,316 1,639
Common stock and additional paid-in capital
24,374 24,348
Accumulated (deficit)
(22,001 ) (21,853 )
Total shareholders’ equity
2,373 2,495
Total liabilities and shareholders’ equity
$ 4,689 $ 4,134

Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)

Six Months Ended
September 30, 2023 September 30, 2022
Operating activities:
Net (loss)
$ (148 ) $ (15 )
Adjustments to reconcile net (loss) to cash
(used in) operating activities:
Depreciation and amortization
44 41
Share-based compensation expense
26 25
Provision for inventory obsolescence, net
64 29
Changes in operating assets and liabilities:
Right of use asset, net
(97 ) (19 )
Accounts receivable
(104 ) 33
Inventories
193 (303 )
Prepaid expenses and other assets
55 50
Accounts payable
47 (143 )
Accrued compensation and other accrued liabilities
(83 ) (36 )
Net cash (used in) operating activities
(3 ) (338 )
Investing activities:
Acquisition of property and equipment
(191 )
Patent costs
(17 ) (10 )
Net cash (used in) investing activities
(17 ) (201 )
Financing activities:
Net proceeds from options exercised
16
Borrowings from secured notes
137 110
Net cash provided by financing activities
137 126
Net increase (decrease) in cash
117 $ (413 )
Cash, beginning of period
189 $ 950
Cash, end of period
$ 306 $ 537

SOURCE: Encision, Inc.

View source version on accesswire.com:
https://www.accesswire.com/802859/encision-reports-second-quarter-fiscal-year-2024-results

Staff

Recent Posts

SeaStar Medical Holding Corporation Investors: Robbins LLP Reminds Shareholders of the SeaStar Medical Holding Corporation (ICU) Class Action

SAN DIEGO--(BUSINESS WIRE)--$ICU #ICU--Robbins LLP reminds investors that a shareholder filed a class action on…

3 hours ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS),…

3 hours ago

Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut

PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo…

3 hours ago

Building telehealth equity: Insights from the Sault Ste. Marie Tribe of Chippewa Indians

New study identifies five recommendations for improving health care equity SAULT STE. MARIE, Mich., July 10, 2024…

3 hours ago

Glytec Announces Major Deals and Continued Market Leadership in Diabetes Care

Glytec Adds New Wins in 1H 2024 to Drive Inpatient Diabetes Market Momentum and Leadership…

3 hours ago

EnsoData expands sleep apnea screening and diagnosis capabilities with new acquisition

New acoustic flow and microphone channels will allow EnsoData to improve access and affordability in…

3 hours ago